文献速递前列腺增生与排尿功能障碍

Aquablation作为良性前列腺增生补救治疗的国际多中心研究

Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study.
PubMed 文献 · BJU Int · 2026-10-07

该回顾性多中心研究分析了2018至2024年间1887例接受Aquablation的男性,其中109例(5.8%)有既往BPH干预史。结果显示补救治疗组与对照组在围手术期并发症、30天再入院率、手术再治疗率及性功能结局上均无显著差异,功能改善也相似。结论认为Aquablation可作为BPH干预后复发下尿路症状的安全有效补救疗法。

要点

  • Aquablation补救治疗组与对照组并发症和再入院率无显著差异
  • 两组最大尿流率、残余尿、IPSS及生活质量改善程度相似
  • 既往BPH干预类型不影响Aquablation的手术时间或并发症

核心结论

  • Aquablation作为BPH干预后复发下尿路症状的补救治疗,安全性和有效性无显著差异。

研究设计与样本

  • 回顾性分析国际多中心数据库2018至2024年1887例连续接受Aquablation的男性,分为既往BPH干预组109例(5.8%)和对照组1778例(94.2%)。

主要发现

  • 两组前列腺体积相似(82.3 vs 78.0 mL;P=0.18)。
  • 围手术期并发症、30天再入院率、手术再治疗率及性功能结局评分均无显著差异(所有P>0.05)。
  • 最大尿流率、残余尿、IPSS及生活质量评分改善均相似(所有P>0.05)。
  • 按既往BPH干预类型亚组分析,手术时间、前列腺体积、中叶存在及并发症率无差异。

临床怎么用

  • 对于既往BPH手术失败且希望保留控尿和性功能的男性,可考虑提供Aquablation作为补救治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal-Wallis tests. Finally, exploratory sub-analyses were performed in the salvage therapy group based on the type of prior BPH intervention. RESULTS: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30-day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post-void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. CONCLUSION: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Leathead A, Lee N, Arezki A, et al. Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study. BJU Int. 2026. PMID: 42843985. doi:10.1111/bju.70481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。